|
|
|
|
|
| |
| 21st December 2007 | | | New Fragment-based Drug Discovery Libraries announced in a commercial collaboration between IOTA Pharmaceuticals Ltd (Cambridge, UK) and Vitas-M Laboratory (Moscow, Russia)IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Vitas-M Laboratory Ltd, based in Moscow, Russia, have joined forces to design and market the next generation of fragment-based drug discovery libraries for early-stage drug discovery. The IOTA Pharmaceuticals - Vitas-M Laboratory collaboration couples IOTA Pharmaceuticals analysis and screening platforms to Vitas-M Laboratory's established chemical synthesis capabilities, to produce a new 4,000-component fragment-based drug discovery (FBDD) screening set. This fragment set is being distributed by both companies immediately. Access to a diverse set of FBDD library compounds enables the rapid progression of new discovery programs from concept to optimised lead, as described in detail on the IOTA website. Dr David Bailey, heading IOTA, commented "Fragment-based drug discovery (FBDD) is a fast, efficient and productive route to NCE discovery. Our combined technologies offer an extensive and reasonably-priced lead discovery tool kit for our pharma and biotech customers." Vitas-M Laboratory is a specialist organic chemistry company which synthesises drug compounds for the pharmaceutical and biotechnology screening markets. For more information about Vitas-M Laboratory, please visit www.vitasmlab.com . |
|
| |
|
| |
| 21st December 2007 | | | New Fragment-based Drug Discovery Libraries announced in a commercial collaboration between IOTA Pharmaceuticals Ltd (Cambridge, UK) and Vitas-M Laboratory (Moscow, Russia)IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Vitas-M Laboratory Ltd, based in Moscow, Russia, have joined forces to design and market the next generation of fragment-based drug discovery libraries for early-stage drug discovery. The IOTA Pharmaceuticals - Vitas-M Laboratory collaboration couples IOTA Pharmaceuticals analysis and screening platforms to Vitas-M Laboratory's established chemical synthesis capabilities, to produce a new 4,000-component fragment-based drug discovery (FBDD) screening set. This fragment set is being distributed by both companies immediately. Access to a diverse set of FBDD library compounds enables the rapid progression of new discovery programs from concept to optimised lead, as described in detail on the IOTA website. Dr David Bailey, heading IOTA, commented "Fragment-based drug discovery (FBDD) is a fast, efficient and productive route to NCE discovery. Our combined technologies offer an extensive and reasonably-priced lead discovery tool kit for our pharma and biotech customers." Vitas-M Laboratory is a specialist organic chemistry company which synthesises drug compounds for the pharmaceutical and biotechnology screening markets. For more information about Vitas-M Laboratory, please visit www.vitasmlab.com . |
|
| |
|
| |
| 25th September 2007 | | | | IOTA Pharmaceuticals, a new Fragment-based Drug Discovery company, established with research centres in Cambridge (UK), Amsterdam (The Netherlands) , and Ahmedabad (India). | | | | Centered on fragment-based drug design, IOTA offers pharmaceutical clients a range of new tools and technologies for drug discovery and lead optimization. IOTA's founder investors are experienced pharmaceutical discovery scientists. Dr Paul England, head of IOTA's screening activities, led Smith-Kline's high-throughput screening operation and was one of the senior executives at the Californian biotechnology company Aurora Biosciences. Dr Sue Boyd, leading IOTA's computational chemistry, has worked in computational chemistry teams at Pfizer, Celltech and Scynexis. Dr Iwan de Esch, based at the VU University in Amsterdam, brings expertise in medicinal chemistry and structure- and fragment-based drug discovery. | | | | These scientists are backed by an experienced commercial team, led by Dr David Bailey, who previously headed up Pfizer's Molecular Sciences Department in Sandwich, UK, and Incyte Pharmaceuticals' European HQ in Cambridge. David is supported by Sunil and Prashant Shah, co-founders of several Cambridge and Far East start-ups, including Oxygen Healthcare, a chemistry company based in Gujarat, India. | | | | This experienced founding group is joined as an investor by the VU University, Amsterdam, a world-leading academic centre of excellence in the Health Sciences. Since its formation in the 1960s, research in the medicinal chemistry department at the VU has focused on the molecular aspects of pharmacology, drug design and chemical synthesis, developing state-of-the-art technologies to discover new chemical entities with potential in human healthcare. |
|
| |
|
| |
| 25th September 2007 | | | | Fragment-based Drug Discovery Initiative announced between the VU University, Amsterdam and IOTA Pharmaceuticals Ltd, Cambridge, UK. | | | | IOTA Pharmaceuticals today announced an alliance in the area of fragment-based drug discovery with The VU University, Amsterdam. The VU-IOTA collaboration couples fragment-based drug discovery (FBDD) to commercially important pharmaceutical targets, thereby enabling the rapid progression of therapeutic targets into new discovery programs. Using the proprietary blend of organic, medicinal and computational chemistry available within the two groups, the collaboration will focus on the development of new drug classes across a range of commercially important therapeutic targets. | | | | The VU University is a world-leading academic centre of excellence in medicinal chemistry. Established by Professors Wijbe Nauta and Henk Timmerman in the 1960's and led since 2000 by Professor Rob Leurs, the Department of Medicinal Chemistry focuses on the application of molecular pharmacology, computational design and chemical synthesis technologies to a range of therapeutically important targets, including the acetylcholine, histamine and chemokine receptors, joined more recently by the protein tyrosine kinases. The Design and Synthesis Group at VU, led by Dr Iwan de Esch, has developed a powerful FBDD platform, combining organic synthesis with structure-guided lead development. In 2006, the group joined forces with other VU scientists in the area of Drug Discovery to establish the VU Drug Discovery Center. | | | | IOTA Pharmaceuticals has been established to provide molecular design, ligand screening and drug discovery services to the pharmaceutical industry. It combines cutting edge drug discovery technologies from European centres of excellence such as VU with cost-effective medicinal chemistry sourced from leading laboratories in India. | | | | Dr Iwan de Esch, leader of the VU initiative, said "We are delighted to work with IOTA to expand our existing fragment-based drug discovery platform. This will be an excellent way to valorise our fundamental research in human health and disease." | | | | Dr David Bailey, leading the FBDD initiative at IOTA, commented "The VU University in Amsterdam is a European centre of excellence in medicinal chemistry, and is at the forefront of technology development in the FBDD area. Together, we will develop a new generation of discovery tools, applying them to emerging therapeutic targets alongside pharmaceutical company collaborators." |
|
| |
|
| |
|
|
|
